Iterum Therapeutics Reports Second Quarter 2024 Financial Results
August 14, 2024 07:00 ET
|
Iterum Therapeutics PLC
-- FDA PDUFA Action Date of October 25, 2024; Advisory Committee Meeting on September 9, 2024— --Cash Runway into 2025, including through PDUFA Action Date-- --Company to Host Conference Call...
Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
August 07, 2024 16:30 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces Expiration and Results of Rights Offering
August 06, 2024 17:30 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and...
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
August 02, 2024 08:00 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Commences Rights Offering
July 22, 2024 07:30 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and...
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
June 21, 2024 08:00 ET
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present Data at ASM Microbe 2024
June 05, 2024 08:00 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, June 05, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
May 31, 2024 08:00 ET
|
Iterum Therapeutics PLC
DUBLIN and CHICAGO, May 31, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Reports First Quarter 2024 Financial Results
May 13, 2024 07:00 ET
|
Iterum Therapeutics PLC
--NDA Resubmitted; FDA Action Expected in Early Q4 24-- --Cash Runway into 2025, including through Potential FDA Approval-- --Company to Host Conference Call Today at 8:30 a.m. EDT-- ...
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
May 06, 2024 08:00 ET
|
Iterum Therapeutics PLC
DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...